×

Pharma fight: What's Allergan worth?

9:08 AM ET Mon, 27 Oct 2014

CNBC's David Faber reports Valeant Pharmaceuticals is willing to increase its bid for Allergan to at least $200 a share. Jim Cramer provides insight to litigation against investor Bill Ackman over insider trading